Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLili RenFNFrancesco NaiHBHongjie Bi

Discussion

Loading...

Member takes

Overview

This research demonstrates the role of METTL1 in leukemia stem cells in myeloid leukemia, suggesting small-molecule inhibitors may offer a new therapeutic approach.

Key Points

  • The aim is to investigate METTL1's role in myeloid leukemia and assess its potential as a therapeutic target.
  • Used genome-wide CRISPR/Cas9 screens to analyze METTL1's role in leukemia stem cells.
  • Conducted transcriptomic analysis on hematopoietic cells from Mettl1 conditional knockout mice.
  • Screened 264,086 small-molecule inhibitors for METTL1 targeting efficacy.
  • Identified METTL1 as crucial for leukemia stem cell self-renewal in myeloid leukemia.
  • Demonstrated small-molecule inhibitors directly target METTL1, reducing leukemia stem cell frequency.
  • In vivo testing showed significant survival benefits in myeloid leukemia models with METTL1 inhibition.

Cite This Study

Ren et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d23ahttps://doi.org/10.1182/blood-2025-2539
View Full Paper
Ask AI
Bookmark
Share